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A behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol
9-tetrahydrocannabinol and
cannabidiol in C57BL/6JArc mice
Abstract
Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing
schizophrenia. The behavioural profiles of the psychotropic cannabis constituent Δ9-tetrahydrocannabinol
(Δ9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of
behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia.
Male adult C57BL/6JArc mice were given 21 daily intraperitoneal injections of vehicle, Δ9-THC (0.3, 1, 3 or
10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg). Δ9-THC produced the classic cannabinoid CB1 receptormediated tetrad of hypolocomotion, analgesia, catalepsy and hypothermia while CBD had modest
hyperthermic effects. While sedative at this dose, Δ9-THC (10 mg/kg) produced locomotor-independent
anxiogenic effects in the open-field and light–dark tests. Chronic CBD produced moderate anxiolytic-like
effects in the open-field test at 50 mg/kg and in the light–dark test at a low dose (1 mg/kg). Acute and
chronic Δ9-THC (10 mg/kg) decreased the startle response while CBD had no effect. Prepulse inhibition
was increased by acute treatment with Δ9-THC (0.3, 3 and 10 mg/kg) or CBD (1, 5 and 50 mg/kg) and by
chronic CBD (1 mg/kg). Chronic CBD (50 mg/kg) attenuated dexamphetamine (5 mg/kg)-induced
hyperlocomotion, suggesting an antipsychotic-like action for this cannabinoid. Chronic Δ9-THC decreased
locomotor activity before and after dexamphetamine administration suggesting functional antagonism of
the locomotor stimulant effect. These data provide the first evidence of anxiolytic- and antipsychotic-like
effects of chronic but not acute CBD in C57BL/6JArc mice, extending findings from acute studies in other
inbred mouse strains and rats.
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Abstract
Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing
schizophrenia. The behavioural proﬁles of the psychotropic cannabis constituent D9-tetrahydrocannabinol
(D9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of
behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia.
Male adult C57BL/6JArc mice were given 21 daily intraperitoneal injections of vehicle, D9-THC (0.3, 1,
3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg). D9-THC produced the classic cannabinoid CB1 receptormediated tetrad of hypolocomotion, analgesia, catalepsy and hypothermia while CBD had modest
hyperthermic eﬀects. While sedative at this dose, D9-THC (10 mg/kg) produced locomotor-independent
anxiogenic eﬀects in the open-ﬁeld and light–dark tests. Chronic CBD produced moderate anxiolytic-like
eﬀects in the open-ﬁeld test at 50 mg/kg and in the light–dark test at a low dose (1 mg/kg). Acute and
chronic D9-THC (10 mg/kg) decreased the startle response while CBD had no eﬀect. Prepulse inhibition
was increased by acute treatment with D9-THC (0.3, 3 and 10 mg/kg) or CBD (1, 5 and 50 mg/kg) and
by chronic CBD (1 mg/kg). Chronic CBD (50 mg/kg) attenuated dexamphetamine (5 mg/kg)-induced
hyperlocomotion, suggesting an antipsychotic-like action for this cannabinoid. Chronic D9-THC decreased
locomotor activity before and after dexamphetamine administration suggesting functional antagonism of
the locomotor stimulant eﬀect. These data provide the ﬁrst evidence of anxiolytic- and antipsychotic-like
eﬀects of chronic but not acute CBD in C57BL/6JArc mice, extending ﬁndings from acute studies in other
inbred mouse strains and rats.
Received 15 December 2008 ; Reviewed 5 January 2009 ; Revised 27 July 2009 ; Accepted 6 August 2009 ;
First published online 29 September 2009
Key words : Antipsychotic, anxiolytic, cannabidiol, mouse, D9-tetrahydrocannabinol.

Introduction
The population risk for schizophrenia is increased by
cannabis use (Henquet et al. 2005 ; Moore et al. 2007).
This increase is reported to be greater in people with
a predisposition to psychosis (Henquet et al. 2005).
D9-tetrahydrocannabinol (D 9-THC), the most abundant
* Address for correspondence : L. E. Long, Ph.D., Schizophrenia
Research Institute, 384 Victoria Rd, Darlinghurst NSW 2010,
Australia.
Tel. : +61 2 9399 1265 Fax : +61 2 9295 8689
Email : l.long@schizophreniaresearch.org.au (L.L.)
Email : t.karl@schizophreniaresearch.org.au (T.K.)

of the >70 cannabis constituents, produces the
euphoric eﬀects sought by recreational users, and
produces psychotomimetic symptoms such as altered
perception and disrupted working memory. Schizophrenia patients show increased susceptibility to these
eﬀects (D’Souza et al. 2005). D9-THC has partial agonist
eﬃcacy at cannabinoid CB1 and CB2 receptors and
exerts many of its central eﬀects via inhibition of
neurotransmitter release by presynaptic CB1 receptors.
Cannabidiol (CBD), another cannabis constituent,
does not produce the psychotropic eﬀects of D9-THC
and antagonizes the eﬀects of CB1/CB2 receptor
agonists (Pertwee, 2008). Interestingly, consumption of
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cannabis with little or no CBD content is associated
with increased incidence of psychotic symptoms
(Morgan & Curran, 2008 ; Rottanburg et al. 1982),
suggesting that CBD may partially attenuate the
psychotomimetic eﬀects of D9-THC or other cannabis
constituents. The therapeutic potential for CBD is
supported by observations of its antipsychotic-like
(Leweke et al. 2000 ; Zuardi et al. 2006a) and anxiolyticlike eﬀects (Crippa et al. 2004, 2009) after acute oral
administration in healthy volunteers. While preliminary data in treatment-resistant schizophrenia patients
suggest that CBD monotherapy is not eﬀective (Zuardi
et al. 2006b), regular oral CBD administration reduces
psychotic symptoms in Parkinson’s disease suﬀerers
(Zuardi et al. 2008).
Reports of CBD eﬀects in rodents are currently restricted to acute studies : CBD exerts anxiolytic-like
(Campos & Guimaraes, 2008 ; Guimaraes et al. 1994 ;
Moreira et al. 2006 ; Onaivi et al. 1990 ; Resstel et al.
2006) and antipsychotic-like (Long et al. 2006 ; Moreira
& Guimaraes, 2005 ; Zuardi et al. 1991) eﬀects in mice
(Swiss, ICR) and rats (Wistar). Interestingly, CBD induces c-fos expression in the rat nucleus accumbens
but not the dorsal striatum, in a pattern similar to that
of clozapine (Guimaraes et al. 2004). To accurately
model the eﬀects of regular cannabis use in humans
and to determine the potential for lasting clinical
eﬃcacy of cannabinoids such as CBD, chronic rodent
behavioural studies are necessary. Furthermore, since
a majority of mutant mouse models are generated
on a C57BL/6J or mixed C57BL/6Jr129SvJ genetic
background, studies in C57BL/6J mice are crucial for
further research.
This study therefore aimed to directly compare the
acute and chronic eﬀects of D9-THC and CBD in
C57BL/6J mice using a multi-tiered battery of schizophrenia- and anxiety-relevant behavioural tests. CBD
eﬀects were compared to the well-characterized eﬀects
of D9-THC in the classic cannabinoid CB1 receptor
agonist ‘tetrad’. Following this, mice were assessed
using a comprehensive multi-tiered battery of behavioural models relevant to positive (spontaneous hyperactivity), negative (social withdrawal, anxiety) and
cognitive (disrupted learning and working memory,
impaired sensorimotor gating) symptoms of schizophrenia during repeated treatment with D9-THC or
CBD. The antipsychotic eﬀect of chronic CBD on druginduced psychotomimetic behaviour was assessed
using acute challenges with the non-competitive
NMDA antagonist MK-801 and the catecholaminergic
stimulant dexamphetamine (Dex). To enable comparison of the eﬀects of repeated treatment, a followup study on acute anxiolytic and potentially anti-

psychotic-like eﬀects of CBD was conducted, using
doses that were behaviourally active in the chronic
study.
Methods
Animals
Test animals were 119 male C57BL/6JArc mice (aged
12–14 wk). Standard social interaction opponents
were 12 male A/JArc mice (aged 9–10 wk) (Animal
Resources Centre, Australia). Mice were maintained
under a 12-h light/red light cycle (lights on 07:00
hours) and pair-housed in Macrolon cages (1144B :
Tecniplast, Australia) containing paper tissues
(Kimwipes1, Kimberley-Clark, Australia) as nesting
material with ad libitum access to water and standard
irradiated mouse feed (Gordon’s Specialty Stockfeeds,
Australia). Chronic experiments were performed in
four sets of 22–24 mice over 8 wk, with treatment randomized and counterbalanced across sets. Follow-up
acute experiments with CBD were performed in a
single set of 29 mice. Research and animal care procedures were approved by the Garvan Institute/
St Vincent’s Hospital Animal Experimentation Ethics
Committee in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientiﬁc
Purposes.
Drug treatment
D9-THC and CBD (THC Pharm GmbH, Germany)
were suspended in a 1 : 1 : 18 mixture of ethanol :
Tween-80 : saline. Dex and MK-801 (Sigma, Australia)
were dissolved in saline. Dose ranges of D9-THC and
CBD were based on previous studies (Boucher et al.
2007 ; Long et al. 2006). Drugs were injected at a volume of 10 ml/kg.
For chronic treatment, mice received 21 consecutive daily intraperitoneal (i.p.) injections of vehicle
(1 : 1 : 18 ethanol : Tween-80 : saline), D9-THC (0.3, 1, 3 or
10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) (n=10). On
day 7 all mice were injected with MK-801 (0.5 mg/kg
i.p.) 35 min after cannabinoid injection. On day 21 all
mice were injected with Dex (5 mg/kg i.p.) 45 min
after cannabinoid injection.
Follow-up experiment
After observing key eﬀects of chronic CBD we investigated the acute behavioural eﬀects of CBD at relevant doses. Separate groups of age-matched male
C57BL/6JArc mice received an i.p. injection of vehicle
or CBD (1 or 50 mg/kg) (n=9–10). Mice were tested in
the elevated plus maze (EPM) (5 min) followed by
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Table 1. Chronic test biography of C57BL/6JArc mice
Day Test
x2
x1
0
1
3
5
7
12
14
15
16
17
18
19
20
21

Time

Prepulse inhibition acclimatization

07:00–10:00
16:00–19:00
Prepulse inhibition acclimatization
07:00–10:00
16:00–19:00
Prepulse inhibition (baseline)
07:00–10:00
16:00–19:00
Body temperature, catalepsy, open ﬁeld, 07:00–11:00
tail ﬂick, prepulse inhibition
15:00–19:00
Body temperature, catalepsy
07:00–10:00
Body temperature, catalepsy
07:00–10:00
Body temperature, catalepsy, MK-801
07:00–11:00
and prepulse inhibition
15:00–19:00
Body temperature, catalepsy
07:00–10:00
Body temperature, catalepsy, tail ﬂick
07:00–10:00
Open ﬁeld
07:00–10:00
Y-maze
07:00–12:00
Light–dark, elevated plus maze
07:00–13:00
Social interaction, prepulse inhibition
07:00–11:00
15:00–19:00
Passive avoidance training
07:00–11:00
Passive avoidance retention test, tail ﬂick 07:00–11:00
Dex and open ﬁeld
07:00–15:00

D9-THC, D9-tetrahydrocannabinol ; CBD cannabidiol, Dex,
dexamphetamine.
Ninety mice were tested over a period of 8 wk. Mice were
injected with either vehicle or D9-THC (0.3, 1, 3 or 10 mg/kg
body weight) or CBD (1, 5, 10 or 50 mg/kg) once daily for
21 d (n=10). On day 7, all mice were injected with MK-801
(0.5 mg/kg) and on day 21 all mice were injected with
Dex (5 mg/kg). The test schedule shows the order in which
tests were completed. Test order and age at commencement
of testing was standardized to avoid diﬀerential impact
of repeated testing on the behavioural parameters
investigated. Tests involving an aversive stimulus
(i.e. electric footshock in passive avoidance) were
performed after tests of anxiety-like behaviour such as the
elevated plus maze to avoid confounds related to the stress
response of the mice.

open-ﬁeld (OF) testing of Dex-induced locomotor
activity (45 min), in which all mice received an injection of Dex (5 mg/kg i.p.) 45 min after vehicle or CBD
injection (in a manner identical to the Dex-induced OF
testing after chronic CBD).
Behavioural testing
Injections commenced at the start of the light cycle
(07:00 hours). On behavioural testing days injections
were staggered within the light cycle to standardize
intervals between injection and testing (Table 1). Mice
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were returned to the home cage following injection
and behavioural testing. Environmental odours were
removed from test apparatus between trials with 70 %
ethanol.
In conducting behavioural testing for schizophrenia, experiments need to target the range of behavioural domains that are aﬀected in the disorder
(Powell & Miyakawa, 2006). Furthermore, behavioural
testing batteries over one or more days have previously yielded informative data on anxiety-related
behaviour (Karl et al. 2008), sensory and motor function (Metz & Schwab, 2004) and defensive behaviour
(Griebel et al. 1999). Ethical considerations prompted
us to investigate more than one behavioural domain in
each group of mice, and during repeated treatment,
the order of behavioural testing proceeded from least
to most aversive, such that tests involving an aversive
stimulus (i.e. electric footshock in passive avoidance)
were performed after tests of anxiety-like behaviour
such as the EPM to avoid confounds related to the
stress response of the mice.
Cannabinoid tetrad A : body temperature, catalepsy
and nociception
Mice were assessed for the classical cannabinoid behavioural tetrad of hypothermia, catalepsy, hypolocomotion and nociception (Compton et al. 1993). Body
temperature was measured 5 min before and 30 min
after injection on days 1, 3, 5, 7, 12 and 14 using a lubricated rectal thermometer (SDR Clinical Technology,
Australia). Catalepsy was measured 20 min after injection on days 1, 3, 5, 7, 12 and 14. The hindpaws of the
mouse were placed on the bench and the forepaws
were placed on a bar (0.2 cm diameter) raised 8 cm oﬀ
the bench surface. The latency for the mouse to place
both forepaws on the bench was recorded. Nociception
was measured with the hot-water tail-ﬂick test 45 min
after injection on days 1, 14 and 20. Mice were gently
wrapped in a towel leaving the tail unrestrained. The
tail tip (1.5 cm) was placed in a beaker of water at room
temperature (25 xC) for 10 s then placed immediately
in a water bath at 52 xC. The latency for the mouse to
ﬂick its tail was recorded. Data are reported as the
mean of three consecutive trials performed for each
mouse, with 2-min inter-trial intervals during which
mice were returned to the home cage.
Cannabinoid tetrad B : spontaneous and Dex-induced
locomotor activity
Locomotor activity was measured by placing mice into
an OF activity chamber (Med Associates Inc., USA).
Horizontal (distance travelled) and vertical activity
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(rearing) in central and peripheral zones were
measured (described previously ; Karl et al. 2007). The
ratio of central to total distance travelled (distance
ratio) and time spent in the central zone were taken as
measures of anxiety (Denenberg, 1969). On days 1 and
15 mice were placed in the OF 35 min after injection
and allowed to explore freely for 10 min. On day 21 of
the chronic study, and in the follow-up study, mice
were placed in the OF 30 min after injection and
allowed to explore freely for 15 min before they were
removed, injected with Dex and immediately returned
to the chamber for a further 30 min.
Light–dark (LD) test
Mice were placed into the opening of the dark compartment of the LD test apparatus (described previously ; Karl et al. 2007) and allowed to explore freely
for 10 min. The ratio of distance travelled in the light
compartment to total distance travelled (distance ratio)
and time spent in the light compartment were taken
as measures of anxiety. Mice were tested with the LD
test 30 min after injection on day 17.
EPM
Mice were placed onto the central platform of the EPM
(described previously ; Karl et al. 2007) facing an enclosed arm and allowed to explore freely for 5 min.
Arm entries, time spent in arms and in the central
platform, rearing and head dipping were scored.
Arm entries were recorded when mice entered the arm
with all four paws. Anxiety-related behaviour was
measured by entries into the open arm from the centre,
percentage of time spent on open arms (divided into
inner and outer halves) and the percentage of openarm entries (open-arm entry ratio) (Hogg, 1996 ;
Pellow et al. 1985). Mice were tested in the EPM 45 min
after injection on day 17 and 25 min after injection in
the acute study.
Social interaction (SI)
SI between pairs of rodents is used to measure anxietylike behaviours (File & Seth, 2003 ; Kask et al. 2001).
Furthermore, reduction in SI models aspects of
social withdrawal observed in schizophrenia patients
(Ellenbroek & Cools, 2000 ; Rung et al. 2005). Test mice
and weight-matched A/JArc standard opponents,
with no prior exposure to either the test arena or to
each other, were placed in opposite corners of a grey
perspex arena (35r35r30 cm ; illumination 50 lx) and
allowed to explore freely for 10 min. Frequency and
total duration of the active socio-positive behaviours
general sniﬃng, anogenital sniﬃng, allogrooming,

following and climbing over/under in each test mouse
were recorded manually. Mice were tested for SI
35 min after injection on day 18.
Prepulse inhibition (PPI)
PPI, an operational measure of sensorimotor gating, is
impaired in schizophrenia patients (Braﬀ et al. 2001 ;
Ludewig et al. 2003). Startle reactivity was measured
using SR-Lab startle chambers (San Diego Instruments, USA). Mice were habituated to this apparatus
for 30 min on two consecutive days. The next day,
mice were tested for baseline PPI, and on the following
day chronic drug treatment began. PPI testing commenced 60 min after injection on days 1 and 18 and
55 min after injection on day 7 (20 min after injection
of MK-801). PPI test sessions consisted of 5-min acclimatization to 70-dB background noise followed
by 105 trials presented in a pseudo-random order :
5r70-dB trials (background) ; 5r80-dB trials ; 5r
100-dB trials ; 15r120-dB trials (startle) and 15 sets of
ﬁve trials comprising a prepulse of either 74, 82 or
86 dB presented 32, 64, 128, 256 or 512 ms prior to a
startling pulse of 120 dB (PPI response). Inter-trial
intervals varied randomly from 10 s to 20 s. Responses
to each trial were calculated as average mean amplitudes detected by the accelerometer. Percentage PPI
( % PPI) was calculated as
startle response (120 dB)xPPI response
r100:
startle response (120 dB)
% PPI was averaged across inter-stimulus (prepulsestartling pulse) intervals to produce a mean % PPI for
each prepulse intensity.
Y-maze
The natural tendency of mice to alternate successive
entry choices of arms in a Y-maze (spontaneous alternation) is used as an assessment of memory retention
(Hughes, 2004). Mice were placed into the centre of a
grey perspex Y-shaped maze (30 cmr10 cmr17 cm,
arms joined by a triangular centre section) and allowed to explore freely for 8 min. Diﬀerent patterns on
each arm wall provided intra-maze directionality cues.
Objects (e.g. a camera tripod) at the end of each arm
provided extra-maze directionality cues. Arm entries
(deﬁned when all four paws were inside the arm) were
recorded manually. The spontaneous alternation score
was calculated as the number of novel triplet entries
(three consecutive entries into diﬀerent arms) expressed as a percentage of the maximum possible
triplet entries (Hodges, 1996). Mice were tested 30 min
after injection on day 16.

Behavioural comparison of D9-THC and CBD in mice
Passive avoidance (PA)
In PA, memory retention is indicated by avoidance of
a naturally less aversive dark compartment after it is
paired with an electrical footshock (Bovet et al. 1969).
This hippocampus-dependent learning test is inﬂuenced by fear of highly illuminated areas and aversive
stimuli (e.g. electrical footshock), and by nociception.
Training and retention trials were performed 30 min
after injection on days 19 and 20, respectively, using a
shuttle box system (TSE Systems, Bad Homburg,
Germany). Latency to enter the dark chamber on each
trial was measured (cut-oﬀ time : 300 s) (previously
described ; Karl et al. 2008). Increased latency in the
retention trial indicated memory of the aversive
stimulus (0.4 mA footshock ; 2 s). Due to apparatus
malfunction several mice did not receive a footshock
and were excluded from further analysis.
Statistical analysis
In analyses for all experiments the vehicle group was
compared separately to the D9-THC (THC 0.3, THC 1,
THC 3 and THC 10) and CBD (CBD 1, CBD 5, CBD 10
and CBD 50) groups. Diﬀerences between treatment
groups were analysed with one-way (factor : treatment) or repeated-measures analyses of variance
(ANOVA) [factors : treatment, 5-min block (Dexinduced locomotor activity), prepulse intensity and
trial (PA)]. Main and interaction eﬀects were identiﬁed
when p<0.05. Planned contrasts were used to determine which treatment groups were signiﬁcantly
diﬀerent to vehicle (simple contrasts), to locate diﬀerences between levels of within-subjects factors (polynomial contrasts) and to locate interactions between
levels of treatment groups and within-subjects factors
(special interaction contrasts). Huynh–Feldt corrections for non-sphericity were applied. Degrees of
freedom, F values and p values from ANOVA are
presented in the Results, and p values from planned
contrasts are indicated in the Figures and Tables by
asterisks (* p<0.05, ** p<0.01, *** p<0.001). Data are
presented as mean¡standard error of the mean
(S.E.M.). Analysis was performed using SPSS 16.0 for
Windows (SPSS Inc., USA).
Results
Cannabinoid tetrad A : body temperature, catalepsy
and nociception
Acute D9-THC (10 mg/kg) produced signiﬁcant hypothermia [one-way ANOVA : F(4, 49)=9.3, p<0.001]
and catalepsy [one-way ANOVA : F(4, 43)=6.0, p<
0.001] (Table 2). There was a trend towards an eﬀect of
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acute D9-THC on nociception (one-way ANOVA :
p=0.08). D9-THC (10 mg/kg) had a signiﬁcant antinociceptive eﬀect on day 14 [one-way ANOVA :
F(4, 44)=3.9, p=0.01] (Table 2), but not on day 20.
CBD (1 and 10 mg/kg) induced a hyperthermic
response on day 7 [one-way ANOVA : F(4, 49)=3.5,
p<0.05] but had no eﬀect on catalepsy or nociception
(Table 2).
Cannabinoid tetrad B : spontaneous
locomotor activity
D9-THC decreased overall distance travelled on day 1
[one-way ANOVA : F(4, 49)=3.5, p<0.05] and day 15
[F(4, 46)=3.6, p<0.05] at 10 mg/kg and on day 21
[F(4, 44)=13.3, p<0.001] at 1, 3 and 10 mg/kg (Fig. 1 a).
D9-THC also decreased peripheral distance travelled
in the OF test on day 1 [one-way ANOVA : F(4, 49)=
3.1, p<0.05] at 10 mg/kg and on day 21 [F(4, 44)=12.8,
p<0.001] at 1, 3 and 10 mg/kg (Fig. 1 b). D9-THC also
decreased the total distance travelled in the LD test
[one-way ANOVA : F(4, 46)=9.6, p<0.001] at 10 mg/kg
(Fig. 1 c) and the total number of arm entries in the
EPM [one-way ANOVA : F(4, 42)=4.0, p<0.01] at 3
and 10 mg/kg (Fig. 1 d), conﬁrming its locomotor
suppressant eﬀects.
In contrast, CBD had no eﬀect on any locomotor
activity measure in the OF test (one-way ANOVA :
p>0.05 ; Fig. 1 e, f). CBD (10 mg/kg) signiﬁcantly
decreased the total distance travelled in the LD test
[one-way ANOVA : F(4, 44)=2.6, p<0.05] (Fig. 1 g).
There was a trend towards an eﬀect of CBD on the
total number of EPM arm entries (one-way ANOVA :
p=0.06 ; Fig. 1 h).
Dex-induced locomotor activity
Chronic
There were main eﬀects of chronic D9-THC (repeatedmeasures ANOVA : F(4, 38)=4.6, p<0.01) and time
(5-min block) [F(2.6, 97.8)=196.2, p<0.001] on the
distance travelled in the OF test on day 21, and a
moderate trend towards an interaction of D9-THC with
time (p=0.09) (Fig. 2 a). An interaction contrast between the 15-min baseline (BL) and 30-min post-Dex
periods showed that Dex increased the distance travelled in all D9-THC-treated groups [BLrpost-Dex :
F(1, 38)=284.7, p<0.001]. The magnitude of this increase was dependent on D9-THC dose [BLrpostDexrD9-THC interaction : F(4, 38)=2.8, p<0.05].
Doses and time-points at which D9-THC attenuated
the Dex-induced increase in locomotor activity were
determined by special interaction contrasts (BLr
speciﬁc post-Dex time-pointrD9-THC) (Fig. 2a).
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Table 2. Body temperature, catalepsy and nociception
Parameter

Day

Vehicle

D9-THC 0.3

D9-THC 1

D9-THC 3

Thermic response :
diﬀerence in body
temperature measured
5 min before and 30 min
after injection (D xC)

1
3
5
7
12
14

1.4¡0.3
1.4¡0.3
1.2¡0.3
0.9¡0.4
1.6¡0.2
1.8¡0.4

2.3¡0.3
1.3¡0.3
1.1¡0.5
1.6¡0.3
1.0¡0.3
1.1¡0.2

2.3¡0.4
1.6¡0.1
1.2¡0.2
1.0¡0.2
0.8¡0.4
1.4¡0.4

1.2¡0.4
1.5¡0.2
1.4¡0.3
1.7¡0.2
1.4¡0.3
1.9¡0.4

Catalepsy : latency to
remove both forepaws
from bar and place on
bench, 20 min after
injection (ms)

1
3
5
7
12
14

58.7¡5.2
48.3¡6.5
44.9¡3.1
49.7¡8.0
39.4¡1.2
36.6¡1.0

71.4¡6.8
44.7¡5.3
43.7¡4.3
45.8¡12.7
69.0¡34.1
43.2¡5.4

68.9¡6.8
70.3¡14.3
85.4¡32.4
49.5¡5.9
56.7¡12.2
56.3¡13.2

93.9¡11.4
48.3¡6.2
53.7¡4.9
53.9¡10.1
51.3¡5.6
62.0¡6.8

Nociception : mean latency
to ﬂick tail immersed in
52 xC water, 45 min after
injection (s), measured
over three consecutive
trials

1
14
20

2.4¡0.1
2.6¡0.3
2.5¡0.3

2.6¡0.2
3.1¡0.4
2.4¡0.3

2.6¡0.2
3.0¡0.2
2.5¡0.3

2.9¡0.3
2.9¡0.2
2.5¡0.3

D9-THC 10
x1.8¡1.0*
0.8¡0.4
1.5¡0.2
1.6¡0.3
1.3¡0.2
1.3¡0.1

CBD 1

CBD 5

CBD 10

CBD 50

1.5¡0.7
1.7¡0.3
1.8¡0.3
2.0¡0.2**
0.8¡0.2
1.6¡0.3

1.4¡0.3
1.0¡0.2
1.2¡0.3
1.0¡0.3
1.3¡0.2
1.2¡0.4

2.2¡0.5
1.2¡0.3
1.2¡0.3
1.8¡0.3*
1.6¡0.4
1.2¡0.2

2.2¡0.5
1.4¡0.1
1.5¡0.2
1.1¡0.2
1.1¡0.2
1.4¡0.2

390.5¡137.9*
66.1¡8.2
57.2¡5.1
45.1¡4.8
63.9¡10.6
56.1¡6.4

50.4¡4.5
46.9¡5.9
37.4¡1.9
41.7¡4.5
42.1¡7.0
38.9¡4.7

114.8¡40.3
76.6¡17.3
41.2¡2.9
40.4¡4.6
54.3¡4.2
49.3¡6.7

64.0¡11.3
39.6¡2.1
38.9¡3.6
38.4¡2.2
38.3¡2.4
38.8¡2.8

55.4¡11.3
59.5¡7.8
47.9¡5.6
42.7¡5.7
79.0¡22.2
49.5¡7.1

3.5¡0.4
3.8¡0.2***
3.1¡0.3

2.3¡0.1
3.0¡0.3
2.5¡0.2

2.0¡0.2
2.5¡0.2
2.3¡0.3

2.4¡0.2
2.5¡0.3
2.3¡0.3

2.2¡0.1
2.4¡0.2
1.8¡0.1

D9-THC, D9-tetrahydrocannabinol ; CBD, cannabidiol.
Body temperature, catalepsy and nociception after injection with D9-THC (0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) on various days of treatment.
Data represent mean (¡S.E.M.), n=8–10.
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle group (one-way ANOVA and planned contrasts).
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20

Vehicle
CBD 1
CBD 5
CBD 10
CBD 50

10

0

Fig. 1. Measures of locomotor activity after injection of D9-tetrahydrocannabinol (THC) (0.3, 1, 3 or 10 mg/kg) or cannabidiol
(CBD) (1, 5, 10 or 50 mg/kg). (a, e). Total distance travelled (open-ﬁeld test, 10 min) on days 1, 15 and 21 of treatment. (b, f)
Distance travelled in the peripheral area (open-ﬁeld test). (c, g) Distance travelled (light-dark test, 10 min) on day 17. (d, h)
Frequency of entries into open and closed arms (elevated plus maze, 5 min) on day 17. Data represent mean¡S.E.M. (n=10).
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle (one-way ANOVA and planned contrasts).

There was a main eﬀect of time (5-min block), but
not CBD, on distance travelled in the OF on day 21
[repeated-measures ANOVA : F(2.2, 92.9)=225.8, p<
0.001] (Fig. 2 b). There was no CBDrtime interaction
(p>0.05). An interaction contrast showed that Dex increased the distance travelled in all CBD-treated groups
[BLrpost-Dex : F(1, 42)=330.1, p<0.001]. The magnitude of this increase was independent of CBD dose
(BLrpost-DexrCBD interaction contrast : p>0.05).

Special interaction contrasts (BLrspeciﬁc post-Dex
time-pointrCBD) showed that CBD (50 mg/kg)
attenuated the Dex-induced increase in locomotor
activity at 35–40 min and 40–45 min (Fig. 2 b).
Acute CBD
In the follow-up experiment investigating the eﬀect of
acute CBD on Dex-induced locomotor activity there
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Fig. 2. Total distance travelled over time (open-ﬁeld test, 45 min) after injection of (a) D9-tetrahydrocannabinol (THC) (0.3, 1,
3 or 10 mg/kg) or (b) cannabidiol (CBD) (1, 5, 10 or 50 mg/kg) during baseline (BL) and after injection of 5 mg/kg Dex
(post-Dex) on day 21 of treatment. Data represent mean¡S.E.M. (n=7–10). # p<0.05 (D9-THC 0.3 vs. vehicle) ; + p<0.05
(D9-THC 1 vs. vehicle) ; # p<0.05, ## p<0.01 (D 9-THC 3 vs. vehicle) ; * p<0.05, ** p<0.01, *** p<0.001 (D9-THC 10 or CBD 50
vs. vehicle) (repeated-measures ANOVA and planned contrasts).

Exploratory activity
Vertical activity in the OF test was decreased by
D9-THC (1, 3 and 10 mg/kg) on day 1 [one-way
ANOVA : F(4, 49)=8.2, p<0.001] and day 15
[F(4, 46)=7.9, p<0.001] and by D9-THC (3 and
10 mg/kg) on day 21 [F(4, 44)=8.4, p<0.001]
(Table 3). This was conﬁrmed by signiﬁcant inhibition
by D9-THC (10 mg/kg) of rearing in the LD test [oneway ANOVA : F(4, 46)=3.5, p<0.05 ; data not shown]
and rearing [one-way ANOVA : F(4, 42)=4.7, p<0.01]
and head dipping [one-way ANOVA : F(4, 42)=3.1,
p<0.05] in the EPM (Table 3).
CBD did not aﬀect vertical activity/rearing in the
OF, LD or EPM tests (one-way ANOVA : p>0.05).
There was a trend towards an eﬀect of CBD on head
dipping in the EPM (one-way ANOVA : p=0.06)
(Table 3).

5000
Vehicle
CBD 1

4000

Distance (cm)

was a main eﬀect of time (5-min block), but not CBD, on
distance travelled in the OF test [repeated-measures
ANOVA : F(2.7, 71.1)=112.0, p<0.001] (Fig. 3). There
was no CBDrtime interaction (p>0.05). Withinsubjects contrasts showed that Dex increased the
distance travelled in all CBD-treated groups [BL vs.
post-Dex : F(1, 26)=211.6, p<0.001]. The magnitude
of this increase was independent of CBD dose (BL vs.
post-DexrCBD interaction contrast : p>0.05). Special
interaction contrasts (BL vs. speciﬁc post-Dex timepointrCBD vs. vehicle) showed that CBD did not
aﬀect the Dex-induced increase in locomotor activity
at any time-point (p>0.05).

CBD 50

3000

Dex (5 mg/kg)
2000
1000
0
0

5

10

15

20

25

30

35

40

45

Time (min)
BL

Post-Dex

Fig. 3. Total distance travelled over time (open-ﬁeld test,
45 min) after a single injection of cannabidiol (CBD) (1 or
50 mg/kg) during baseline (BL) and after injection of
5 mg/kg Dex (post-Dex). Data represent mean¡S.E.M.
(n=9–10).

Anxiety measures
Chronic
D9-THC (10 mg/kg) signiﬁcantly decreased the time
spent in the central zone of the OF test on day 15 [oneway ANOVA : F(4, 46)=2.8, p<0.05] and day 21
[F(4, 44)=3.4, p<0.05] (Fig. 4 a) and decreased the
distance ratio on day 1 [F(4, 49)=3.9, p<0.01], day 15
[F(4, 46)=3.1, p<0.05] and day 21 [F(4, 44)=8.6,
p<0.001] (Fig. 4 b). Similarly, D9-THC (10 mg/kg) decreased the time spent in the light compartment [oneway ANOVA : F(4, 46)=3.5, p<0.05] and the distance

Rearing (EPM) (n)
Head dipping (EPM) (n)

D9-THC, D9-tetrahydrocannabinol ; CBD, cannabidiol ; OF, open-ﬁeld ; EPM, elevated plus maze.
Frequency of vertical activity (OF test, 10 min) and rearing and head dipping (EPM, 5 min) after injection of D9-THC (0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) on various
days of treatment.
Data represent mean (¡S.E.M.), n=7–10.
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle group (one-way ANOVA and planned contrasts).

93.2¡7.3
82.3¡10.6
69.9¡10.7
15.5¡1.2
17.6¡2.0
88.0¡10.5
53.3¡6.3
63.0¡6.2
13.4¡1.4
12.0¡1.3
111.9¡11.5
75.9¡8.8
63.8¡7.9
12.3¡1.8
10.5¡0.9
104.7¡17.0
67.9¡9.6
79.6¡9.3
12.3¡2.2
12.4¡2.8
32.4¡16.9***
19.1¡4.3***
4.3¡1.7***
2.8¡1.1**
4.3¡1.5**
29.9¡13.2***
38.5¡5.1**
35.3¡6.7**
7.4¡2.4
9.7¡2.7
1
15
21
17
17
Vertical activity (OF) (n)

107.9¡6.0
62.9¡7.6
68.3¡7.6
11.2¡2.0
13.1¡1.5

75.8¡7.4
53.9¡5.8
61.6¡7.0
12.0¡1.7
12.2¡1.5

67.8¡9.9*
45.4¡5.9*
55.3¡15.5
12.1¡2.1
9.9¡1.9

CBD 1
D9-THC 10
Day
Parameter

Table 3. Exploratory activity

Vehicle

D9-THC 0.3

D9-THC 1

D9-THC 3

CBD 5

CBD 10

CBD 50
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ratio [one-way ANOVA : F(4, 46)=2.8, p<0.05] in the
LD test (Fig. 4 c, d). There was a trend towards an eﬀect
of D9-THC on time spent in the inner open arm in the
EPM (one-way ANOVA : p=0.08), but no eﬀect on the
open-arm entry ratio (data not shown).
In contrast, CBD (50 mg/kg) increased the time
spent in the central zone of the OF test on day 15 [oneway ANOVA : F(4, 48)=3.5, P<0.05] (Fig. 4 e). There
was a trend towards a signiﬁcant eﬀect of CBD on the
distance ratio on day 15 (one-way ANOVA : p=0.07)
(Fig. 4 f). In the LD test, CBD (1 mg/kg) signiﬁcantly
increased the time spent in the light compartment
[one-way ANOVA : F(4, 44)=3.0, p<0.05] and the distance ratio [F(4, 44)=2.8, p<0.05] (Fig. 4 g, h). There
was a moderate trend towards an eﬀect of CBD on
time spent in the inner open arm in the EPM (one-way
ANOVA : p=0.09), but no eﬀect on the open-arm entry
ratio or percentage of time spent on open arms (data
not shown).
Acute CBD
In the follow-up experiment investigating the eﬀect of
CBD in the EPM there was no eﬀect of CBD on total
number of EPM arm entries, percentage time in the
open arms, ratio of open-arm entries to total arm
entries, time in the centre zone, head dipping, or
rearing (one-way ANOVA : p>0.05 ; data not shown).
Startle response and PPI
All mice displayed identical startle response and PPI
at baseline testing 1 d prior to the ﬁrst injection (data
not shown). There was a main eﬀect of prepulse intensity on PPI (p<0.001) and a signiﬁcant linear contrast between levels of prepulse intensity (p<0.001) on
all test days, indicating that PPI increased with increasing prepulse intensity.
D9-THC (10 mg/kg) decreased the startle response
on day 1 [one-way ANOVA : F(4, 48)=3.1, p<0.05]
and day 18 [F(4, 44)=3.1, p<0.05] (Table 4). There was
no eﬀect of D9-THC on the startle response when mice
were treated with MK-801 (data not shown).
There was no eﬀect of CBD on startle response
on any day (one-way ANOVA : p>0.05). There was
no main eﬀect of D9-THC on PPI on days 1, 7 or 18
(repeated-measures ANOVA : p>0.05, data not shown
for day 7) (Fig. 5a, b). There was a signiﬁcant interaction between D9-THC and prepulse intensity on day 1
[F(6.5, 71.4)=5.0, p<0.001] and day 18 [F(7.0, 70.2)=
5.6, p<0.001]. Planned contrasts showed that acute
D9-THC (0.3, 3 and 10 mg/kg) signiﬁcantly increased
PPI (Fig. 5 a).
There was a main eﬀect of CBD on PPI on day 1
[repeated-measures ANOVA : F(4, 44)=4.9, p<0.01]
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Fig. 4. Anxiety-related measures after injection of D9-tetrahydrocannabinol (THC) (0.3, 1, 3 or 10 mg/kg) or cannabidiol (CBD)
(1, 5, 10 or 50 mg/kg). (a, e) Time spent in the central area (open-ﬁeld test, 10 min) on days 1, 5 and 21 of treatment. (b, f) Distance
ratio (open-ﬁeld test). (c, g) Time spent in the light compartment (light–dark test, 10 min) on day 17. (d, h) Distance ratio
(light–dark test). Data represent mean¡S.E.M. (n=7–10). * p<0.05, ** p<0.01, *** p<0.001 vs. vehicle group (one-way ANOVA
and planned contrasts).

(Fig. 5 c), but not on day 7 (data not shown) or day 18
(p>0.05) (Fig. 5 d). There was no CBDrprepulse
intensity interaction (p>0.05). Planned contrasts
showed that acute (1, 5 and 50 mg/kg) (Fig. 5c) and
chronic (1 mg/kg) (Fig. 5 d) CBD increased PPI.
Social interaction
D9-THC did not alter total SI time (one-way ANOVA :
p>0.05), but decreased the combined frequency of the

social behaviours general sniﬃng, anogenital sniﬃng,
allogrooming, following and climbing over/under
[one-way ANOVA : F(4, 45)=13.2, p<0.001] (Table 5).
D9-THC reduced general sniﬃng frequency [one-way
ANOVA : F(4, 45)=18.6, p<0.001] at 3 and 10 mg/kg
and its duration [one-way ANOVA : F(4, 45)=3.9,
p<0.01] at 10 mg/kg (Table 5). D9-THC (10 mg/kg)
also decreased anogenital sniﬃng frequency [one-way
ANOVA : F(4, 45)=4.5, p<0.01].
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Table 4. Startle response
Day

Vehicle

D9-THC 0.3

D9-THC 1

D9-THC 3

D9-THC 10

CBD 1

CBD 5

CBD 10

CBD 50

1
18

58.1¡4.0
66.8¡4.9

49.8¡3.4
56.0¡9.0

50.4¡6.2
65.3¡7.9

48.8¡4.3
50.1¡6.0

35.7¡4.6**
39.0¡5.2*

44.3¡6.6
54.3¡10.5

57.9¡4.7
71.0¡8.1

52.9¡3.5
64.3¡4.9

52.5¡5.8
65.6¡6.1

D9-THC, D9-tetrahydrocannabinol ; CBD, cannabidiol.
Startle response (arbitrary units) following 120 dB acoustic stimuli [prepulse inhibition (PPI), 30 min] after injection with D9-THC
(0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) on various days of treatment.
Data represent mean (¡S.E.M.), n=8–10.
* p<0.05, ** p<0.01 vs. vehicle group (one-way ANOVA and planned contrasts).
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Fig. 5. % Prepulse inhibition (PPI) after injection of D9-tetrahydrocannabinol (THC) (0.3, 1, 3 or 10 mg/kg) or cannabidiol
(CBD) (1, 5, 10 or 50 mg/kg) on (a, c) day 1 and (b, d) day 18 of treatment. Data represent mean¡S.E.M. (n=8–10).
* p<0.05, *** p<0.001 vs. vehicle group (repeated-measures ANOVA and planned contrasts).

There was no eﬀect of CBD on SI (one-way
ANOVA : p>0.05) (Table 5).
Y-maze
There was no eﬀect of treatment on the percentage
of novel entry triplets, indicating equal spontaneous
alternation. Neither D9-THC nor CBD aﬀected the
number of total arm entries (data not shown).

Passive avoidance
A main eﬀect of trial on the latency to enter the
dark chamber in vehicle- and D9-THC-treated mice
[repeated-measures ANOVA : F(1, 26)=31.0, p<0.001]
indicated that all mice learned to avoid the dark
chamber after training (Fig. 6 a). There was no main
eﬀect of D9-THC (p>0.05) but there was a signiﬁcant
D9-THC treatmentrtrial interaction [F(4, 26)=3.4,

D9-THC, D 9-tetrahydrocannabinol ; CBD, cannabidiol.
Duration and frequency of general sniﬃng, anogenital sniﬃng and total social interaction (SI) (SI test, 10 min) with a standard opponent A/JArc mouse after injection with D9-THC
(0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) on day 18 of treatment.
Data represent mean (¡S.E.M.), n=8–10.
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle group (one-way ANOVA and planned contrasts).

30.0¡2.1
52.3¡3.4
11.6¡1.6
48.6¡6.0
80.3¡7.6
29.1¡3.7
51.3¡3.9
15.8¡2.8
48.5¡6.5
80.1¡6.9
30.6¡2.9
55.5¡3.6
16.1¡2.0
50.2¡4.5
84.3¡5.9
General sniﬃng duration (s)
General sniﬃng (n)
Anogenital sniﬃng (n)
Total social interaction duration (s)
Total social interaction (n)

23.5¡1.2
48.1¡2.0
16.3¡2.1
43.7¡2.9
79.3¡5.4

28.2¡2.3
49.6¡4.1
16.6¡2.9
48.3¡3.6
83.4¡6.4

24.7¡1.7
43.1¡2.5*
13.6¡2.1
52.2¡9.5
71.5¡6.0

18.7¡2.7**
21.4¡2.2***
5.7¡1.2*
50.9¡13.1
34.6¡3.2***

24.5¡1.8
47.7¡3.6
16.8¡2.8
42.4¡4.6
77.9¡8.3

CBD 10
CBD 5
CBD 1
D9-THC 10
D9-THC 3
D9-THC 1
D9-THC 0.3
Vehicle
Parameter

Table 5. Social interaction

27.1¡2.5
51.0¡3.2
19.7¡1.4
49.6¡3.8
86.6¡4.7
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p<0.05]. Planned interaction contrasts showed that
D9-THC (10 mg/kg) increased the latency to enter the
dark chamber in the retention trial.
CBD-treated mice also learned to avoid the dark
chamber after training, indicated by a main eﬀect of
trial [repeated-measures ANOVA : F(1, 31)=37.6,
p<0.001] (Fig. 6 b). There was no main eﬀect of CBD or
a CBDrtrial interaction.
Discussion
This study is the ﬁrst to compare acute and
chronic eﬀects of two cannabinoids, the prototypical
psychoactive constituent D9-THC and the nonpsychotomimetic CBD, in a battery of schizophrenia
and anxiety-relevant behavioural tests in male adult
C57BL/6JArc mice. The major ﬁndings were : (i) acute
D9-THC and CBD enhanced PPI ; (ii) chronic CBD, but
not D9-THC, enhanced PPI ; (iii) chronic D9-THC and
CBD, but not acute CBD, attenuated Dex-induced
hyperlocomotion and (iv) chronic, but not acute, CBD
produced moderate anxiolytic-like eﬀects.
D9-THC produced the cannabinoid ‘ tetrad’ of acute
eﬀects (Compton et al. 1993), consistent with its accepted proﬁle as a partial CB1 agonist (Pertwee, 2008).
In contrast, CBD had no eﬀect on tetrad measures of
catalepsy, nociception or locomotion and produced
only modest hyperthermia, suggesting that acute CBD
does not produce the sedative or hypolocomotor
eﬀects of D9-THC in C57BL/6JArc mice (Compton et al.
1992 ; Onaivi et al. 1990 ; Varvel et al. 2006).
Our novel ﬁnding that D9-THC (acute) enhanced
PPI in C57BL/6JArc mice adds to an inconclusive
database on the eﬀects of D9-THC on PPI and
represents the ﬁrst such report of CBD eﬀects. The
results may be species- and strain-dependent since
cannabinoid agonists have previously disrupted PPI
in ddY mice (Nagai et al. 2006) and rats (Schneider &
Koch, 2002), whereas in other animal models, D9-THC
may disrupt (e.g. in socially isolated rats ; Malone &
Taylor, 2006) or enhance PPI (e.g. in neuregulin 1
mutant mice ; Boucher et al. 2007). Importantly, we
observed PPI eﬀects in the absence of changes to the
startle response except with 10 mg/kg D9-THC, which
concomitantly enhanced PPI and decreased the startle
response.
In contrast, few studies exist on the eﬀects of CBD on
PPI, and our ﬁndings that acute (1, 5 and 50 mg/kg)
and chronic (1 mg/kg) CBD enhanced PPI represent
the ﬁrst such report of CBD’s eﬀects. While these
ﬁndings do not in themselves represent antipsychoticlike eﬀects, it is interesting to speculate on whether
such improved baseline sensorimotor gating as that
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Fig. 6. Latency to enter dark chamber (passive avoidance test, 5 min) 30 min after injection of (a) D9-tetrahydrocannabinol
(THC) (0.3, 1, 3 or 10 mg/kg) or (b) cannabidiol (CBD) (1, 5, 10 or 50 mg/kg) on days 19 (training) and 20 (retention) of treatment.
Data represent mean¡S.E.M. (n=5–8). * p<0.05 vs. vehicle group (repeated-measures ANOVA and planned contrasts).

observed with acute and chronic CBD here might interact with the eﬀect of genetic or pharmacological
challenges on PPI. Previously, CBD alone had no eﬀect
on PPI in Swiss mice but dose-dependently increased
the startle response and reversed an MK-801-induced
PPI deﬁcit at 5 mg/kg (Long et al. 2006). We aimed
to assess whether repeated treatment with CBD
could reverse the eﬀects of MK-801, which dosedependently disrupts PPI in rodents (Mansbach &
Geyer, 1989 ; Varty et al. 2001 ; Yee et al. 2004) and mimics the glutamatergic hypofunction thought to occur
in schizophrenia. However, MK-801 did not disrupt
PPI in our vehicle group. Since mice experienced two
PPI sessions prior to testing under MK-801, PPI enhancement may have masked its disruptive eﬀect
(Plappert et al. 2006). Future studies will conﬁrm
whether repeated CBD treatment can reverse the
psychotomimetic eﬀect of MK-801 on PPI.
We also investigated the eﬀect of chronic D9-THC or
CBD on the locomotor response to the psychostimulant Dex. Dex produced a typical increase in spontaneous locomotor activity that was attenuated in
mice pre-treated with D9-THC (3 or 10 mg/kg) or CBD
(50 mg/kg). D9-THC-treated mice showed decreased
baseline activity, suggesting a functional antagonism
by D9-THC of Dex-induced hyperlocomotion. In contrast, CBD attenuated Dex-induced hyperlocomotion
without altering baseline locomotor activity. Importantly, acute CBD at low (1 mg/kg) or high (50 mg/kg)
doses did not alter Dex-induced hyperlocomotion.
Although previous studies report that at similar doses
acute CBD reduced Dex- and ketamine-induced
hyperlocomotion (Moreira & Guimaraes, 2005), our
divergent results may be due to genetic diﬀerences
between mouse strains used. Further studies may
elucidate potential cumulative eﬀects of CBD on

brain regions associated with the response to the
psychostimulant. Indeed, changes in hypothalamic
c-fos protein expression and catecholamine release
in the nucleus accumbens core following intracerebroventricular CBD administration in rats
(Murillo-Rodriguez et al. 2006) raise intriguing possibilities for mechanisms that may underlie the eﬀects
we observed. Our study is the ﬁrst to report the eﬀects
of chronic CBD on behaviours related to schizophrenia
and suggests that it might modulate such measures as
PPI and Dex-induced hyperlocomotion.
Another area of therapeutic potential for CBD is in
treating anxiety. We observed that low- and high-dose
chronic CBD produced anxiolytic-like eﬀects, in contrast to the anxiogenic eﬀects observed with acute and
chronic D9-THC. The signiﬁcant eﬀects of D 9-THC and
CBD on distance ratios in the OF and LD tests provide
measures of anxiety-related behaviour that are relatively independent of locomotor activity. Interestingly,
acute doses of CBD (1 and 50 mg/kg) that produced
anxiolytic-like eﬀects in the OF and LD tests after
chronic administration had no eﬀect in the EPM. This
contrasts with previous reports of anxiolytic-like
eﬀects of acute CBD (Campos & Guimaraes, 2008 ;
Guimaraes et al. 1994 ; Moreira et al. 2006 ; Onaivi et al.
1990) and may again be due to species and strain
eﬀects (Belzung, 2001). In the SI test, which measures
anxiety and social withdrawal, D9-THC (10 mg/kg)
reduced general sniﬃng and anogenital sniﬃng frequency, consistent with reports after high dose (van
Ree et al. 1984) or chronic D9-THC treatment (Quinn
et al. 2008). However, sedation might have reduced the
overall activity of our D9-THC (10 mg/kg)-treated
mice. In contrast, CBD did not alter baseline SI, consistent with previous reports in rats (Malone et al.
2009 ; van Ree et al. 1984). Overall, we provide novel
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evidence that chronic treatment with CBD produces
anxiolytic-like eﬀects in the LD test in C57BL/6JArc
mice.
Learning and working memory are behavioural
domains of therapeutic interest for schizophrenia,
which is marked by cognitive deﬁcits (Elvevag &
Goldberg, 2000). In the present study D9-THC had no
eﬀect on spontaneous alternation or total arm entries
in the Y-maze. Interestingly, D9-THC did not signiﬁcantly reduce the number of arm entries, perhaps due
to the less aversive nature of the Y-maze compared
with the anxiogenic components of the LD or OF
apparatus. In the PA test, D9-THC dose-dependently
increased the latency to enter the aversive stimuluspaired dark chamber, an unexpected eﬀect since
higher doses of D9-THC generally disrupt short-term
memory (Fadda et al. 2004 ; Quinn et al. 2008 ; Silva de
Melo et al. 2005). Nevertheless, D9-THC no longer induced analgesia at this stage of treatment, excluding
nociceptive interference with the aversive nature of
the electric footshock, and any locomotor eﬀects were
controlled for in the statistical analysis. CBD did not
aﬀect spontaneous alternation in the Y-maze nor
latency to enter the dark chamber in the PA test. These
results, combined with previous observations that
acute CBD had no eﬀect in the radial arm maze
(Lichtman et al. 1995) and that CBD-rich cannabis
extracts had no eﬀect in the Morris water maze
(Fadda et al. 2006), suggest that CBD does not disrupt
memory.
In conclusion, using a comprehensive behavioural
phenotyping strategy in order to capture a number
of features associated with schizophrenia and anxiety
we provide the ﬁrst report that chronic CBD facilitates
sensorimotor gating, exerts anxiolytic-like eﬀects
and attenuates Dex-induced hyperlocomotion in
C57BL/6JArc mice. Meanwhile, acute, but not chronic,
D9-THC facilitates PPI. The chronic onset of the CBD
eﬀects and their complex dose-dependency are novel
ﬁndings that raise intriguing avenues for further
studies of its therapeutic potential. In particular, investigations using speciﬁc behavioural models of
schizophrenia, particularly in genetic mouse models,
will be useful in the future.
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